Table 2 Disposition of patients at 12Â months
Status | N = 49 |
|---|---|
On treatment | 37 (75.5%) |
Treatment discontinued | 12 (24.5%) |
 Adverse events | 9 (18.4%) |
     Thrombocytopenia | 5 (10.2%) |
     Hyperbilirubinemia | 2 (4.1%) |
     Heart disease | 1 (2.0%) |
     Headache | 1 (2.0%) |
 No molecular response | 2 (4.1%) |
 Disease progression | 1 (2.0%) |
Median actual dose intensity, mg/day (range) | 651 (198–800) |